sur ABSCIENCES (EPA:AB)
AB Science to Present Masitinib Update in Upcoming Webcast
AB Science SA has announced a live webcast scheduled for January 28, 2025. This event will run from 5.30pm to 6.45pm CET, aiming to provide insights into the masitinib platform. The webcast will feature prominent figures from the company, including co-founder and CEO Alain Moussy. Dr. Olivier Hermine, a distinguished hematologist from Necker-Enfants Malades Hospital in Paris, will also be present.
Masitinib, a key compound in AB Science's proprietary portfolio, is being developed for applications in various fields such as oncology and neurological diseases. Additionally, it holds registration for use in veterinary medicine.
The webcast will be accessible through ZOOM, providing both audio and presentation. This event aims to update stakeholders on the developments and prospects within AB Science's research.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABSCIENCES